Old Web
English
Sign In
Acemap
>
authorDetail
>
Emre Yildirim
Emre Yildirim
Novo Nordisk
Internal medicine
Medicine
Adverse effect
Semaglutide
Endocrinology
4
Papers
30
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.
2020
BMJ Open
Richard E. Pratley
Vanita R. Aroda
Andrei-Mircea Catarig
Ildiko Lingvay
Jörg Lüdemann
Emre Yildirim
Adie Viljoen
Show All
Source
Cite
Save
Citations (2)
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
2020
BMJ open diabetes research & care
Ildiko Lingvay
Thomas Kruse Hansen
Stanislava Macura
Michel Marre
Michael A. Nauck
Raymond de la Rosa
Vincent Woo
Emre Yildirim
John P H Wilding
Show All
Source
Cite
Save
Citations (11)
Glucagon‐like peptide‐1 receptor expression in the human eye
2018
Diabetes, Obesity and Metabolism
Josephine B. Hebsgaard
Charles Pyke
Emre Yildirim
Lotte Bjerre Knudsen
Steffen Heegaard
Peter Helding Kvist
Show All
Source
Cite
Save
Citations (15)
Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy.
2016
Medical Hypotheses
Mehmet Gokhan Culha
Ahmet Cagkan Inkaya
Emre Yildirim
Serhat Ünal
Ege Can Serefoglu
Show All
Source
Cite
Save
Citations (2)
1